POZEN Inc. POZN today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. (Par) from launching a generic version of Treximet.
Par, which POZEN believes has 180 days of exclusivity for its generic product as the first company to file an Abbreviated New Drug Application with the United States Food and Drug Administration, could launch the product into the United States market, at risk, after regulatory exclusivity for Treximet expires on April 15, 2011.
The motion was filed in the United States District Court for the Eastern District of Texas, where the Company's ongoing patent litigation against Par and several other generic companies is pending. There can be no assurance that the motion will be granted.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in